Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome
and for those tesamorelin-treated patients completing the 26-week treatment period that were re-randomized to tesamorelin (T-T group) or re-randomized to placebo, 36.6% and 32.0%, respectively, had impaired glucose tolerance, while 2.0% re-randomized to tesamorelin and 6.0% re-randomized to placebo had diet-controlled diabetes mellitus
Continuing maintenance therapy helps prevent this by supporting ongoing appetite control and metabolic stability
At recent list prices, the drugs may cost upward of $12,000 annually
Erdman has over 20 years of experience in the field of cosmetic dermatology and oversees all treatments performed at Madison Medispa
Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional